PhaseRx appoints Peggy Phillips to board of directors
Ms. Phillips served as the chief operating officer for Immunex from 1999 until 2002 when the company was acquired by Amgen. During her 16-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales, and marketing.
As general manager for Enbrel, she was responsible for clinical development, process development and regulatory affairs, as well as the launch, sales and marketing of the product.
Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for 10 years.
Ms. Phillips previously served on the boards of Immunex Corporation (1996-2002), the U.S. Naval Academy Foundation (2002-2010), Western Wireless (2004-2005), Portola Pharmaceuticals (2006-2013), and Tekmira Pharmaceuticals (2014-2015). She currently serves on the board of Dynavax Technologies.
She holds a B.S. and an M.S. in microbiology from the University of Idaho. She will be replacing Richard Ulevitch, Ph.D., of 5AM Ventures, who is resigning from the board. ■
LATEST MOVES FROM Washington
- Juno Therapeutics appoints Rupert Vessey to board
- HomeStreet appoints Mark R. Ruh as interim CFO
- Avalara appoints Tony Susak as general manager
- Red Lion Hotels adds two to board
- Expedia appoints Chelsea Clinton to board
More inside POST
ZTE swings to 2016 loss on U.S. fine Earnings